← Oncology Approval Tracker

FDA DECISION ·

Tepmetko

tepotinib · EMD Serono

Traditional approvalTraditional conversionNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic non-small cell lung cancer and a MET exon 14 skipping alteration.

LAMPGEN ANALYSIS

Why it matters

Traditional approval confirmed the label for the oral MET inhibitor after expanded follow-up and additional patients in VISION.

What research teams should watch

Verify the exact skipping alteration and track edema, medication interruptions and longitudinal response.

PRIMARY RECORDS

Sources